Orchid Pharma (BOM:524372) EPS (Basic): ₹4.01 (TTM As of Mar. 2026)


BOM:524372 Orchid Pharma Ltd BOM:524372
57 GF Score
Price ₹988.20
GF Value ₹810.49
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Orchid Pharma EPS (Basic)?

Orchid Pharma BOM:524372 +3.05% 57 EPS (Basic) is ₹4.01 as of Mar. 2026. GuruFocus rates BOM:524372 with a GF Score™ of 57/100 and a GF Value™ of ₹810.49 (Modestly Overvalued). The stock has 10 warning signs investors should review.

Orchid Pharma's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹4.69. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.01.

Orchid Pharma's EPS (Diluted) for the three months ended in Mar. 2026 was ₹4.69. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.01.

Orchid Pharma's EPS without NRI for the three months ended in Mar. 2026 was ₹4.58. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 5.07.

During the past 12 months, Orchid Pharma's average EPS without NRIGrowth Rate was -75.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was 14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Orchid Pharma's highest 3-Year average EPS without NRI Growth Rate was 60.90% per year. The lowest was -13.80% per year. And the median was 16.70% per year.

Orchid Pharma  (BOM:524372) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Orchid Pharma EPS (Basic) Related Terms

Orchid Pharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Orchid Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orchid Pharma EPS (Basic) Chart

Orchid Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.48 11.35 19.06 19.65 4.05

Orchid Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.40 2.94 -1.13 -2.49 4.69
BOM:524372
57GF Score
Orchid Pharma Ltd BOM:524372
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orchid Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Orchid Pharma's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(205.47-0)/50.733
=4.05

Orchid Pharma's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(237.802-0)/50.704
=4.69

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹4.01 mean?
Orchid Pharma (BOM:524372) has a EPS (Basic) of ₹4.01 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Orchid Pharma and its competitors.
Is Orchid Pharma's EPS (Basic) too high?
Orchid Pharma's current EPS (Basic) is ₹4.01. Overall, Orchid Pharma has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's EPS (Basic) compare to ZTS?
Orchid Pharma's EPS (Basic) of ₹4.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Orchid Pharma and its competitors. Orchid Pharma's current EPS (Basic) is ₹4.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orchid Pharma (BOM:524372) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹810.49, compared to a current price of ₹988.20 — trading 21.9% above its estimated fair value. The current EPS (Basic) is ₹4.01. Orchid Pharma's overall GF Score™ is 57/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Orchid Pharma (BOM:524372), the current EPS (Basic) is ₹4.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orchid Pharma (BOM:524372) Overvalued in 2026?

Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued. The current stock price of ₹988.20 is trading 21.9% above its estimated GF Value™ of ₹810.49. GuruFocus considers Orchid Pharma to be Modestly Overvalued.

Key valuation signals for BOM:524372:

  • EPS (Basic): ₹4.01
  • GF Value™: ₹810.49 vs. price of ₹988.20 (21.9% above fair value)
  • GF Score™: 57/100 with 10 warning signs

No single metric tells the full story. See the BOM:524372 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orchid Pharma Business Description

Other Exchanges ORCHPHARMA:India
Address Sector 74A, 15th Floor, Tower-1, DLF Corporate Greens, Narsinghpur, Gurugram, HR, IND, 122004
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
57GF Score

Get the complete analysis for BOM:524372

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹988.20
Price
₹810.49
GF Value